ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.00%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,314.995
-0.53%
Brent Oil
80.875
0.09%
Bitcoin
69,047.03
1.92%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Evelo Biosciences Inc (EVLO)

  7. Evelo Biosciences Inc (EVLO) News

Evelo Biosciences (EVLO)

Evelo Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EVLO
DateTimeSourceHeadlineSymbolCompany
26/01/202422:30Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EVLOEvelo Biosciences Inc
26/01/202422:29Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
26/01/202422:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
26/01/202422:27Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EVLOEvelo Biosciences Inc
26/01/202422:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
12/12/202312:43Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EVLOEvelo Biosciences Inc
12/12/202312:42Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
04/12/202311:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
01/12/202312:11Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
21/11/202311:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
09/11/202322:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
09/11/202301:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
09/11/202301:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
09/11/202301:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
03/11/202320:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
03/11/202320:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
03/11/202320:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
27/10/202322:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
17/10/202312:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
17/10/202312:00GlobeNewswire Inc.Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisNASDAQ:EVLOEvelo Biosciences Inc
14/09/202301:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
14/09/202301:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
14/09/202301:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
21/08/202322:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
21/08/202322:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
21/08/202312:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
18/08/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVLOEvelo Biosciences Inc
14/08/202313:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
14/08/202312:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
14/08/202312:30GlobeNewswire Inc.Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:EVLO

Your Recent History

TSXV
VER
BOV
FRIO3
METALFRIO ON
BIT
P12JI2
BNP PARIBAS ISSUANCE
BIT
S27464
Societe Generale Effekten
BOV
TIMS3
TIM ON
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved